Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Launched by WEST CHINA HOSPITAL · Apr 22, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the potential benefits of a treatment called adjuvant therapy for patients who have had surgery for a rare and aggressive type of liver cancer known as primary hepatic sarcomatoid carcinoma. Adjuvant therapy is given after surgery to help prevent the cancer from coming back, but there isn’t much solid evidence yet on how effective it is for this specific type of cancer. By studying patients who have undergone liver surgery and evaluating their recovery, the researchers hope to find out if this treatment can improve their outcomes.

To be eligible for this trial, patients must have had surgery to remove their liver cancer and need to have a confirmed diagnosis of primary hepatic sarcomatoid carcinoma based on their pathology results. Patients who received other treatments before their surgery, such as radiation or chemotherapy, or those with other types of sarcomas or concurrent cancers, unfortunately, won’t be able to participate. If someone qualifies and joins the study, they can expect to be monitored closely to see how well they do after surgery with or without adjuvant therapy. The results from this trial could help establish better treatment guidelines for future patients with this type of liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients who underwent liver resection
• • 2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
• Exclusion Criteria:
• • 1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
• • 2. patients diagnosed with other specific types of sarcomas;
• • 3. patients with concurrent other malignancies during the course of PHSC;
• • 4. patients who were lost to follow-up or lacked essential clinical data.